Introduction
============

Skin cutaneous melanoma (SKCM) is a highly aggressive skin cancer, which arises from the malignant transformation of melanocytes in the basal layer of the epidermis ([@b1-ol-0-0-11287],[@b2-ol-0-0-11287]) and has a poor prognosis, with a 5-year overall survival (OS) of 91.8% worldwide ([@b3-ol-0-0-11287]). The number of new cases of SKCM that will emerge in 2019 was estimated to be 96,480, with the mortality estimated to be 7,230 ([@b4-ol-0-0-11287],[@b5-ol-0-0-11287]). Therefore, there is an urgent need to identify novel biomarkers and prognostic predictive indicators for the detection and management of SKCM.

The JAK-STAT signaling pathway serves a crucial role in cell immunity, division and death, and in tumor formation ([@b6-ol-0-0-11287]). The two key components involved in this pathway are Janus kinases (JAKs) and signal transducer and activator of transcription proteins (STATs), which are encoded by the genes *JAK* (*JAK1, JAK2, JAK3* and *TYK2*) and *STAT* (*STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B* and *STAT6*), respectively ([@b6-ol-0-0-11287]).

A previous study has demonstrated that the key genes involved in the JAK-STAT signaling pathway are associated with several types of cancer, including breast ([@b7-ol-0-0-11287],[@b8-ol-0-0-11287]), ovarian, lung, brain ([@b9-ol-0-0-11287]) and colorectal ([@b10-ol-0-0-11287]) cancer, and that their differential expression may result in different prognosis outcomes in different types of cancer. However, few reports about the association between these genes and SKCM are available, and further investigation analyzing the prognostic value of gene expression in the JAK-STAT signaling pathway in SKCM is needed. The aim of the present study was to identify the prognostic values of the expression of genes involved in the JAK-STAT signaling pathway in patients with SKCM based on data derived from public databases and bioinformatics analysis, and to explore the underlying mechanism that may affect the outcome in SKCM prognosis.

Materials and methods
=====================

### Data preparation

The Cancer Genome Atlas (TCGA; <https://cancergenome.nih.gov>; accessed on September 10th 2018 was used to obtain the gene expression and clinical data of patients with SKCM, including sex, age and tumor stage. A total of 458 SKCM cases were selected after removing the cases with missing mRNA expression or clinical data and 0-day survival time.

### Functional analysis of key genes in the JAK-STAT signaling pathway

The Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway map was generated using the KEGG website (<https://www.kegg.jp>; accessed on September 10th 2018 ([@b11-ol-0-0-11287]--[@b13-ol-0-0-11287]). Gene ontology (GO) term analysis, including biological function (BP), molecular function (MF) and cellular component (CC), as well as KEGG enrichment analysis for JAK and STAT gene families, were performed using the Database for Annotation, Visualization and Integrated Discovery version 6.8 (DAVID; <https://david.ncifcrf.gov/tools.jsp>; accessed on September 13th 2018. The official gene symbol was used as the identifier; the species was *Homo sapiens* ([@b14-ol-0-0-11287],[@b15-ol-0-0-11287]).

### Gene interaction and association analysis

Gene-gene interaction analysis was performed using gene multiple association network integration algorithm (GeneMANIA; <http://genemania.org>; accessed on September 15th 2018 using the default parameters ([@b16-ol-0-0-11287],[@b17-ol-0-0-11287]). The correlation between JAK and STAT pathway gene expression in SKCM was evaluated using the Pearson\'s correlation coefficient; P\<0.01 was considered to indicate a significant correlation. Protein-protein interaction analysis was performed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; <https://string-db.org>; accessed on September 25th 2018. The minimum required interaction score was 0.400 ([@b18-ol-0-0-11287],[@b19-ol-0-0-11287]).

### Patient grouping based on gene expression level

Patients with SKCM were divided into high or low expression groups using the median value, and the vertical scatter plots were generated.

### Survival analysis

Kaplan-Meier survival plots with log-rank test were used to evaluate the OS for the high and low-expression groups of each gene and clinicopathological characteristics. In addition, the Cox proportional hazard regression model was used for univariate and multivariate survival analyses, and 95% confidence intervals (CIs) and hazard ratios (HRs) were calculated. Joint effects analysis was performed for the combination of genes identified as significant by the survival analysis.

### Nomogram

A nomogram was used to evaluate the association between JAK and STAT gene expression and clinical information in SKCM. In addition, the risk rank for each gene and clinicopathological characteristic, including age, sex and tumor stage, was evaluated by the risk points and total points. Survival rates (1-, 3- and 5-year) were also scored. A high score was associated with a low survival rate.

### Gene set enrichment analysis (GSEA)

To investigate the potential underlying mechanism of the differential expression of *STAT1, STAT3, STAT4, STAT5B* and *STAT6* in SKCM, GSEA version 3.0 software (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>; accessed on September 20th 2018 ([@b20-ol-0-0-11287]) was used, and the difference in the expression levels in the low and high-expression groups for each gene was analyzed with reference gene sets, which were based on the Molecular Signatures Database sets c2 (KEGG gene sets, c2.all.v6.2.symbols.gmt), c5 \[Gene Ontology (GO) gene sets, c5.all.v6.2.symbols.gmt\] and c6 (oncogenic signatures gene sets, c6.all.v6.2.symbols.gmt) ([@b21-ol-0-0-11287]). The permutation number was set to 1,000. Those enrichment gene sets revealed by GSEA as exhibiting a nominal P\<0.05 and a false discovery rate (FDR) \<0.25 were considered to indicate a statistically significant difference. The default parameters were used in GSEA software.

### Statistical analysis

Statistical analysis was performed using SPSS v.25.0 software (IBM Corp.) and R 3.3.5 (<https://www.r-project.org/>). Kaplan-Meier survival analysis and the log-rank test were used to calculate the OS and P-values for all associations. The Cox proportional hazards regression model was used for univariate and multivariate survival analyses. HRs and 95% CIs were calculated using the Cox proportional hazards regression model with adjustment for influential clinical characteristics such as race, sex, age, Tumor-Node-Metastasis stage ([@b22-ol-0-0-11287]) and body mass index. FDRs in the GSEA were adjusted for multiple testing with the Benjamini-Hochberg procedure to control the FDR ([@b23-ol-0-0-11287],[@b24-ol-0-0-11287]). P\<0.05 was considered to indicate a statistically significant difference. Vertical scatter plots and survival curves were generated in GraphPad Prism v.7.0 (GraphPad Software, Inc.).

Results
=======

### Clinicopathological characteristics of patients with SKCM

The clinicopathological data of the 458 patients included in the present study are presented in [Table I](#tI-ol-0-0-11287){ref-type="table"}. Race, age and tumor stage were significantly associated with median survival time (P=0.003, P\<0.001 and P\<0.001, respectively; [Table I](#tI-ol-0-0-11287){ref-type="table"}). After normalization, only *JAK1, STAT1, STAT3, STAT4, STAT5B* and *STAT6* genes mRNA expression were observed.

### Bioinformatics analysis of JAK and STAT genes

The KEGG pathway map of the JAK-STAT signaling pathway is represented in [Fig. 1](#f1-ol-0-0-11287){ref-type="fig"} (KEGG map no. 04630; <http://www.genome.jp/dbget-bin/www_bget?pathway:map04630>). The GO term and KEGG enrichment analysis for JAK and STAT genes included BP ([Figs. S1A](#SD1-ol-0-0-11287){ref-type="supplementary-material"} and [S2A](#SD1-ol-0-0-11287){ref-type="supplementary-material"}), CC ([Figs. S1B](#SD1-ol-0-0-11287){ref-type="supplementary-material"} and [S2B](#SD1-ol-0-0-11287){ref-type="supplementary-material"}), MF ([Figs. S1C](#SD1-ol-0-0-11287){ref-type="supplementary-material"} and [S2C](#SD1-ol-0-0-11287){ref-type="supplementary-material"}) and KEGG ([Figs. S1D](#SD1-ol-0-0-11287){ref-type="supplementary-material"} and [S2D](#SD1-ol-0-0-11287){ref-type="supplementary-material"}). The DAVID result for the combination of JAK and STAT gene families suggested that the JAK and STAT signaling pathways were associated with cell migration, the mitogen-activated protein kinase (MAPK) cascade, cell differentiation ([Fig. 2A](#f2-ol-0-0-11287){ref-type="fig"}), cytosol, cytoplasm ([Fig. 2B](#f2-ol-0-0-11287){ref-type="fig"}), DNA binding, ATP binding, signal transducer activity ([Fig. 2C](#f2-ol-0-0-11287){ref-type="fig"}), the PI3K-AKT signaling pathway and the pancreatic cancer signaling pathway ([Fig. 2D](#f2-ol-0-0-11287){ref-type="fig"}).

### Gene interaction and association analysis

The gene-gene interaction network was analyzed separately in the *JAK* family ([Fig. S3](#SD1-ol-0-0-11287){ref-type="supplementary-material"}) and in the *STAT* family ([Fig. S4](#SD1-ol-0-0-11287){ref-type="supplementary-material"}), as well as in their combination ([Fig. 3A](#f3-ol-0-0-11287){ref-type="fig"}). The protein-protein interaction network is presented in [Fig. 3B](#f3-ol-0-0-11287){ref-type="fig"}.

Pearson\'s correlation coefficient was used to analyze the correlation between JAK and STAT genes in SKCM tissues based on the TCGA dataset ([Fig. 3C](#f3-ol-0-0-11287){ref-type="fig"}). The results suggested that, with the exception of *STAT6*, the expression of STAT genes (*STAT1, STAT3, STAT4* and *STAT5B*) in SKCM strongly correlated with each other.

Scatter plots of the expression of all JAK and STAT genes in TCGA dataset (using the median as the cut-off value) are presented in [Fig. 3D](#f3-ol-0-0-11287){ref-type="fig"}. The difference between the high and low-expression groups was statistically significant (P\<0.001).

### Survival analysis

The results of univariate survival analysis of JAK and STAT genes are presented in [Fig. 4](#f4-ol-0-0-11287){ref-type="fig"} and [Table II](#tII-ol-0-0-11287){ref-type="table"}. High expression levels of *STAT1, STAT3, STAT4* and *STAT5B*, and low expression levels of *STAT6* were associated with a favorable prognosis (P\<0.05). Multivariate Cox proportional hazards regression analysis identified that sex, race, age and tumor stage were associated with the prognosis of patients with SKCM. Multivariate survival analysis, in agreement with univariate survival analysis, demonstrated that high expression of *STAT1, STAT3, STAT4* and *STAT5B*, and low expression of *STAT6* was associated with a favorable prognosis (adjusted P\<0.001; HR, 0.595; 95% CI, 0.455--0.778; adjusted P=0.018; HR, 0.725; 95% CI, 0.555--0.947; adjusted P\<0.001; HR, 0.590; 95% CI, 0.450--0.773; adjusted P=0.007; HR, 0.690; 95% CI, 0.526--0.940; and adjusted P=0.026; HR, 0.737; 95% CI, 0.563--0.964, respectively; [Table II](#tII-ol-0-0-11287){ref-type="table"}).

### Predictive nomogram and joint effects analysis

Independent factors, including age, sex, tumor stage and mRNA expression, were integrated into the prognostic nomogram to predict the clinical outcomes of patients with SKCM ([Fig. 5A](#f5-ol-0-0-11287){ref-type="fig"}). Age, tumor stage, and *JAK1, STAT1, STAT4, STAT5B* and *STAT6* expression levels exhibited major contributions as prognostic signatures in the risk scores (range, 0--100).

All survival related genes, including *STAT1, STAT3, STAT4, STAT5B* and *STAT6*, were selected and grouped to perform joint effects analysis. The grouping information of joint effects analysis is presented in [Tables III](#tIII-ol-0-0-11287){ref-type="table"}--[VI](#tVI-ol-0-0-11287){ref-type="table"}. The group number with simple Arabic numerals represented all gene selected groups ([Table III](#tIII-ol-0-0-11287){ref-type="table"}); Arab numerals with brackets are 4 selected genes ([Table IV](#tIV-ol-0-0-11287){ref-type="table"}); Lowercase Roman numerals are 3 selected genes ([Table V](#tV-ol-0-0-11287){ref-type="table"}); Capitalized Roman numerals are 2 selected genes ([Table VI](#tVI-ol-0-0-11287){ref-type="table"}). The combination of genes with favorable prognosis had a better effect on the OS (univariate survival analysis; P\<0.05; [Table VII](#tVII-ol-0-0-11287){ref-type="table"} and [Figs. 5B-G](#f5-ol-0-0-11287){ref-type="fig"}, [6A-J](#f6-ol-0-0-11287){ref-type="fig"} and [7A-J](#f7-ol-0-0-11287){ref-type="fig"}).

### GSEA

The detailed GSEA results, including KEGG, GO and oncogenic signatures, are shown in [Tables SI](#SD2-ol-0-0-11287){ref-type="supplementary-material"}, [SII](#SD3-ol-0-0-11287){ref-type="supplementary-material"} and [SIII](#SD4-ol-0-0-11287){ref-type="supplementary-material"}, respectively, and in [Fig. 8](#f8-ol-0-0-11287){ref-type="fig"}. High expression of *STAT1* was significantly associated with immune response (normalized P=0.002; FDR=0.243; [Fig. 8A](#f8-ol-0-0-11287){ref-type="fig"}), cell adhesion (normalized P=0.002; FDR=0.206; [Fig. 8B](#f8-ol-0-0-11287){ref-type="fig"}; normalized P=0.010; FDR=0.241; [Fig. 8D](#f8-ol-0-0-11287){ref-type="fig"}) and WNT protein binging (normalized P=0.006; FDR=0.261; [Fig. 8C](#f8-ol-0-0-11287){ref-type="fig"}). By contrast, low expression of *STAT4* was associated with WNT protein binding (normalized P=0.001; FDR=−0.234; [Fig. 8E](#f8-ol-0-0-11287){ref-type="fig"}), whereas high expression of *STAT5B* was associated with gene silencing (normalized P=0.002; FDR=0.249; [Fig. 8F](#f8-ol-0-0-11287){ref-type="fig"}).

Discussion
==========

In the Surveillance, Epidemiology, and End Results Program database, the 5-year relative survival is 98% for prostate cancer, 89.9% for breast cancer and 19.4% for lung cancer ([@b3-ol-0-0-11287],[@b4-ol-0-0-11287]). For melanoma, a 91.8% 5-year relative survival rate appears satisfactory; however, the 5-year relative survival for patients with tumor stage IV is only 3% ([@b22-ol-0-0-11287],[@b25-ol-0-0-11287]).

The JAK-STAT signaling pathway serves a crucial role in functions such as cell proliferation, differentiation, migration and apoptosis, cell survival in hematopoiesis, immune cell development, stem cell maintenance and organismal growth processes ([@b26-ol-0-0-11287]--[@b28-ol-0-0-11287]). Dysfunction in the JAK-STAT signaling pathway is associated with diseases such as cancer and immune disorders ([@b6-ol-0-0-11287],[@b27-ol-0-0-11287]). In the JAK-STAT signaling pathway, the *JAK* family comprises *JAK1, JAK2, JAK3* and *TYK2*, and the *STAT* family comprises *STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B* and *STAT6* ([@b6-ol-0-0-11287],[@b29-ol-0-0-11287]). A number of diseases are associated with the expression levels of genes of the JAK-STAT signaling pathway. A previous study has demonstrated that increased expression of *STAT3* or *STAT1*, but not of both, was present in melanoma compared with that in benign nevi or skin melanocytes ([@b30-ol-0-0-11287]). In addition, active *STAT3* was present in melanoma ([@b30-ol-0-0-11287]). By contrast, overexpression of microRNA (miR)-214 in a lung cancer cell line reduced the expression of *JAK1*, which inhibited cell proliferation and colony formation, and suppressed cell migration and invasion ([@b31-ol-0-0-11287]). In papillary thyroid cancer, downregulation of *JAK1* by miR-520a-3p inactivated the JAK-STAT signaling pathway ([@b32-ol-0-0-11287]).

However, studies that explored the association between the prognosis of melanoma and the JAK-STAT signaling pathway are limited. In the present study, the expression of *JAK* and *STAT* family genes in melanoma was investigated based on TCGA data. The observation that JAK-STAT gene expression is associated with the MAPK signaling pathway is in agreement with a previous study, which demonstrated that the JAK-STAT signaling pathway is integrated with the MAPK signaling pathway ([@b33-ol-0-0-11287]--[@b35-ol-0-0-11287]) and is associated with melanoma ([@b36-ol-0-0-11287]). Expression of *JAK2, JAK3, TYK2, STAT2* and *STAT5B* was not observed after normalizing mRNA expression in the present study, suggesting that these genes were expressed at a low level. High expression of *STAT1, STAT3, STAT4* and *STAT5B*, as well as low expression of *STAT6*, were associated with a favorable prognosis of patients with SKCM. These results are consistent with other studies, in which high expression of *STAT1* was associated with favorable prognosis in high-grade serous ovarian cancer (HGSC) ([@b37-ol-0-0-11287]), colorectal cancer ([@b38-ol-0-0-11287]) and esophageal squamous cell carcinoma ([@b39-ol-0-0-11287]). In addition, high expression of *STAT1* in HGSC was significantly associated with the recruitment of intraepithelial CD8^+^ T cells, which enhanced the prognostic and predictive value of intratumoral CD8^+^ T cells in HGSC ([@b40-ol-0-0-11287]), potentially due to tumors with high *STAT1* mRNA expression exhibiting elevated expression of genes specific for tumor-associated macrophages and immunosuppressive T lymphocytes ([@b7-ol-0-0-11287]). The results of the enrichment analysis in the present study also revealed that *STAT1* was associated with the immune response, which suggested that *STAT1* may accelerate the immune cell response to cancer ([@b41-ol-0-0-11287]). However, high *STAT1* expression was associated with poor prognosis in glioblastoma ([@b42-ol-0-0-11287]), and breast ([@b7-ol-0-0-11287],[@b8-ol-0-0-11287]), ovarian, lung, blood and brain ([@b9-ol-0-0-11287]) cancer.

In contrast to that of *STAT1, STAT3* expression is downregulated in malignant pleural mesothelioma ([@b43-ol-0-0-11287]); however, the prognostic value of this association has not been reported. The majority of studies on *STAT3* and cancer prognosis have demonstrated that phosphorylated *STAT3* is associated with a poor outcome in colorectal cancer ([@b10-ol-0-0-11287]), multiple myeloma ([@b44-ol-0-0-11287]) and urothelial carcinoma ([@b45-ol-0-0-11287]). In addition, *STAT4* has been detected in several types of cancer, including prostate ([@b46-ol-0-0-11287]), breast ([@b47-ol-0-0-11287]), gastric ([@b48-ol-0-0-11287]) and ovarian ([@b49-ol-0-0-11287]) cancer. The upregulation of *STAT4* in hepatocellular carcinoma is associated with favorable prognosis, possibly due to the expression of *STAT4* in the immune cells; however, the function and mechanism of *STAT4* in non-immune cells remains unknown ([@b50-ol-0-0-11287]). High expression of *STAT5B* in astrocytoma is associated with poor prognosis ([@b51-ol-0-0-11287]), whereas high expression of *STAT6* is associated with poor prognosis in colon cancer ([@b52-ol-0-0-11287]).

The potential effects of these associations require further exploration. For instance, colorectal carcinoma cell lines exhibiting low *STAT1* and high *STAT3* expression levels are associated with enhanced tumor growth in xenografts; by contrast, xenograft cell lines with high *STAT1* and low *STAT3* levels grew slowly ([@b53-ol-0-0-11287]). Thus, gene interactions may influence the cancer outcome. The different expression level of these two genes in different types of cancer may serve different roles. Joint effects analysis in the present study suggested that any combination of the tested markers may have a higher prognostic value compared with that of any individual biomarker.

The STAT gene family affects cell differentiation ([@b54-ol-0-0-11287]), invasion ([@b55-ol-0-0-11287]--[@b57-ol-0-0-11287]), adhesion ([@b58-ol-0-0-11287]) and migration ([@b59-ol-0-0-11287]), as well as cell cycle ([@b60-ol-0-0-11287]--[@b62-ol-0-0-11287]) and colony formation ([@b39-ol-0-0-11287],[@b63-ol-0-0-11287]) through the JAK-STAT signaling pathway; these processes are associated with the occurrence, development and outcome of cancer. The potential mechanism of how these genes affect prognosis should be further studied.

The present study investigated the prognostic value of the key genes in the JAK-STAT signaling pathway; only STAT genes were demonstrated to affect the prognosis of SKCM. In melanoma research, no golden standard exists for diagnosis or prognosis that would serve a similar role as the hairy-related 2 gene in breast cancer or prostate specific antigen in prostate cancer. Certain genes may act as biomarkers to predict the prognosis and mechanism of SKCM, including RAF (Raf proto-oncogene), MEK (MAP/ERK kinase), MAPK, RAS, myelocytomatosis oncogene and S100 calcium binding protein ([@b64-ol-0-0-11287]--[@b69-ol-0-0-11287]). However, further research is required to identify a golden standard for predicting melanoma.

There were certain limitations in the present study. Firstly, only *JAK* expression data were reported following normalization; additional mRNA expression data are needed to further confirm these observations. Secondly, this is an association study. Further research is needed to explore the function and mechanism of the genes of the JAK-STAT signaling pathway identified in the present study in patients with SKCM. Another limitation of the current study is the limited sample size. Improved design and larger sample size studies are necessary to validate these results. Finally, there were no expression standards to measure whether the gene expression was high or low.

To the best of our knowledge, the present study is the first to evaluate the association between the expression of genes of the JAK-STAT signaling pathway and OS in patients with SKCM, and to identify the joint effects of prognostic values among the five identified genes. Overall, the results of the present study provided a novel insight into the function of these genes in SKCM clinical outcomes, and may be further utilized in the clinic for predicting the prognosis of SKCM.

In conclusion, the combination of the highly expressed *STAT1, STAT3, STAT4* and *STAT5B* genes, and the lowly expressed *STAT6* gene is associated with a favorable prognosis in patients with SKCM, and may be used as a novel biomarker for predicting the prognosis of patients with SKCM. The expression of the genes in the *STAT* family may affect the prognosis of SKCM by accelerating the immune response and immune cell activity, and by involving the MAPK signaling pathway. Further studies are required to validate these findings.
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![KEGG pathway map of the JAK-STAT signaling pathway obtained from the KEGG website. KEGG, Kyoto Encyclopedia of Genes and Genomes; JAK, Janus kinase; STAT, signal transducer and activator of transcription.](ol-19-03-1928-g00){#f1-ol-0-0-11287}

###### 

Analysis of enriched GO terms and KEGG pathways for JAK and STAT genes obtained using Database for Annotation, Visualization and Integrated Discovery. (A) Biological process results of GO functional enrichment analysis. (B) Cellular component results of GO functional enrichment analysis. (C) Molecular function results of GO functional enrichment analysis. (D) KEGG pathway analysis results. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; *JAK*, Janus kinase; *STAT*, signal transducer and activator of transcription; MAPK, mitogen-activated protein kinase.
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![Correlation and association analysis for JAK and STAT genes in SKCM (A) Gene interaction network of JAK and STAT genes generated by GeneMANIA. (B) Protein-protein interaction network generated using the STRING database. (C) Pearson\'s correlation coefficients for *JAK1, STAT1, STAT3, STAT4, STAT5B* and *STAT6* gene expression levels. (D) Scatter plots of *JAK1, STAT1, STAT3, STAT4, STAT5B* and *STAT6* gene expression level in The Cancer Genome Atlas database. GeneMANIA, gene multiple association network integration algorithm; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins; *STAT*, signal transducer and activator of transcription; SKCM, skin cutaneous melanoma; error bars in the scatter plots, mean ± SD.](ol-19-03-1928-g03){#f3-ol-0-0-11287}

![Prognostic value of the expression of key genes of the JAK-STAT signaling pathway for overall survival. (A-F) Kaplan-Meier survival plots for all patients with skin cutaneous melanoma according to (A) *JAK1*, (B) *STAT1*, (C) *STAT3*, (D) *STAT4*, (E) *STAT5B* and (F) *STAT6* expression. *JAK*, Janus kinase; *STAT*, signal transducer and activator of transcription.](ol-19-03-1928-g04){#f4-ol-0-0-11287}

###### 

Nomogram and joint-effects survival analysis of JAK and STAT genes. (A) Nomogram for predicting the 1-, 3- and 5-year event (death) based on risk scores and clinical information. (B) Joint effects analysis of the influence of combined gene expression on overall survival in patients with skin cutaneous carcinoma. (C-G) Joint effects analysis of the influence of combined expression of four selected genes on overall survival in patients with skin cutaneous melanoma according to (C) group ([@b1-ol-0-0-11287])-([@b3-ol-0-0-11287]), (D) group ([@b4-ol-0-0-11287])-([@b6-ol-0-0-11287]), (E) group ([@b7-ol-0-0-11287])-([@b9-ol-0-0-11287]), (F) group ([@b10-ol-0-0-11287])-([@b12-ol-0-0-11287]) and (G) group ([@b13-ol-0-0-11287])-([@b15-ol-0-0-11287]). *JAK1*, Janus kinase 1; *STAT*, signal transducer and activator of transcription. NOS, non-specific.
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###### 

(A-J) Joint effects analysis of the effects of combined expression of three selected genes on overall survival in patients with skin cutaneous melanoma according to (A) group i-iii, (B) group iv-vi, (C) group vi-ix, (D) group x-xii, (E) group xiii-xv, (F) group xvi-xvii, (G) group xix-xxi, (H) group xxii-xxiv, (I) group xxv-xxvii and (J) group xxviii-xxx.
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###### 

(A-J) Joint effects analysis of the influence of combined expression of two selected genes on overall survival in patients with skin cutaneous melanoma according to (A) group I--III, (B) group IV--VI, (C) group VI--IX, (D) group X--XII, (E) group XIII--XV, (F) group XVI--XVII, (G) group XIX--XXI, (H) group XXII--XXIV, (I) group XXV--XXVII and (J) group XXVIII--XXX.
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###### 

GSEA of genes expressed in patients with skin cutaneous melanoma. (A-D) GSEA of the c5 reference gene sets for the high *STAT1* expression group. (A) c5 item negative regulation of adaptive immune response, (B) c5 item positive regulation of cell-cell adhesion, (C) c5 item regulation of CD4 positive alpha beta T cell activation and (D) c5 item regulation of cell-cell adhesion. (E) GSEA of the c5 reference gene sets for the low *STAT4* expression group. (F) GSEA of the c5 reference gene sets for the high *STAT5B* expression group. *STAT*, signal transducer and activator of transcription; GSEA, gene set enrichment analysis; NES, normalized enrichment score; FDR, false discovery rate; NOM, nominal.
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###### 

Survival analysis based on clinical information.

  Characteristic                                              Patients (n=458)   No. of events (%)   MST (days)   HR (95% CI)                 Crude P-value
  ----------------------------------------------------------- ------------------ ------------------- ------------ --------------------------- -------------------------------------------------------
  Race                                                                                                                                        0.003^[a](#tfn1-ol-0-0-11287){ref-type="table-fn"}^
    Caucasian                                                 435                210 (48.3)          2,454        0.337 (0.166--0.687) Ref.   
    Other                                                     13                 8 (61.5)            636                                      
    Unknown                                                   10                                                                              
  Sex                                                                                                                                         0.345
    Male                                                      284                146 (51.4)          2,421        Ref. 0.872 (0.657--1.158)   
    Female                                                    174                73 (42.0)           2,367                                    
  Age (years)                                                                                                                                 \<0.001^[a](#tfn1-ol-0-0-11287){ref-type="table-fn"}^
    ≤60                                                       239                115 (48.1)          3,196        0.587 (0.445--0.773) Ref.   
    \>60                                                      219                104 (47.5)          1,864                                    
  Tumor stage^[b](#tfn2-ol-0-0-11287){ref-type="table-fn"}^                                                                                   \<0.001^[a](#tfn1-ol-0-0-11287){ref-type="table-fn"}^
    Early                                                     231                108 (46.8)          3,195        0.547 (0.411--0.728) Ref.   
    Advanced                                                  191                96 (50.3)           1,927                                    
    Unknown                                                   36                                                                              

P\<0.05.

Due to the small sample size of certain tumor stages, two groups were used to reduce the probability of statistical errors. MST, median survival time; HR, hazard ratio; CI, confidence interval; Ref., reference group.

###### 

Prognostic survival analysis based on high or low expression of JAK and STAT family genes

  Gene       Patients (n=458)   No. of events (%)   MST (days)   Crude HR (95% CI)           Crude P-value                                           Adjusted HR^[b](#tfn4-ol-0-0-11287){ref-type="table-fn"}^ (95% CI)   Adjusted P-value^[b](#tfn4-ol-0-0-11287){ref-type="table-fn"}^
  ---------- ------------------ ------------------- ------------ --------------------------- ------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------
  *JAK1*                                                                                                                                                                                                                  
    Low      229                99 (43.2)           2,588        Ref. 1.056 (0.808--1.379)   0.690                                                   Ref. 0.950 (0.720--1.253)                                            0.716
    High     229                120 (52.4)          2,365                                                                                                                                                                 
  *STAT1*                                                                                                                                                                                                                 
    Low      229                119 (52.0)          1,910        Ref 0.587(0.449--0.767)     \<0.001^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^   Ref. 0.595 (0.455--0.778)                                            \<0.001^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^
    High     229                100 (47.3)          3,259                                                                                                                                                                 
  *STAT3*                                                                                                                                                                                                                 
    High     229                113 (49.3)          2,030        Ref. 0.701 (0.537--0.915)   0.009^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^     Ref. 0.725 (0.555--0.947)                                            0.01^8[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^
    Low      229                106 (46.3)          3,080                                                                                                                                                                 
  *STAT4*                                                                                                                                                                                                                 
    Low      229                121 (52.8)          1,785        Ref. 0.562 (0.430--0.735)   \<0.001^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^   Ref. 0.590 (0.450--0.773)                                            \<0.001^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^
    High     229                98 (42.8)           3,176                                                                                                                                                                 
  *STAT5B*                                                                                                                                                                                                                
    Low      229                117 (48.1)          2,022        Ref. 0.675 (0.516--0.884)   0.004^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^     Ref. 0.690 (0.526--0.940)                                            0.007^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^
    High     229                102 (47.4)          3,139                                                                                                                                                                 
  *STAT6*                                                                                                                                                                                                                 
    High     229                115 (50.4)          2,184        Ref. 0.731 (0.559--0.956)   0.022^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^     Ref. 0.737 (0.563--0.964)                                            0.026^[a](#tfn3-ol-0-0-11287){ref-type="table-fn"}^
    Low      229                104 (47.2)          3,139                                                                                                                                                                 

P\<0.05.

Adjusted for age and tumor stage. *JAK1*, Janus kinase 1; *STAT*, signal transducer and activator of transcription; MST, median survival time; HR, hazard ratio; CI, confidence interval; Ref., reference.

###### 

Grouping information for joint effects analysis of all *STAT* genes.

      Composition                                    
  --- ------------- ---------- ---------- ---------- ---------
  1   Low           Low        Low        Low        High
  2   **High**      Low        Low        Low        High
      Low           **High**   Low        Low        High
      Low           Low        **High**   Low        High
      Low           Low        Low        **High**   High
      Low           Low        Low        Low        **Low**
  3   **High**      **High**   Low        Low        High
      **High**      Low        **High**   Low        High
      **High**      Low        Low        **High**   High
      **High**      Low        Low        Low        **Low**
      Low           **High**   **High**   Low        High
      Low           **High**   Low        **High**   High
      Low           **High**   Low        Low        **Low**
      Low           Low        **High**   **High**   High
      Low           Low        **High**   Low        **Low**
      Low           Low        Low        **High**   **Low**
  4   **High**      **High**   **High**   Low        High
      **High**      **High**   Low        **High**   High
      **High**      Low        **High**   **High**   High
      Low           **High**   **High**   **High**   High
      **High**      **High**   Low        Low        **Low**
      **High**      Low        **High**   Low        **Low**
      Low           **High**   **High**   Low        **Low**
      **High**      Low        Low        **High**   **Low**
      Low           **High**   Low        **High**   **Low**
      Low           Low        **High**   **High**   **Low**
  5   **High**      **High**   **High**   **High**   High
      **High**      **High**   **High**   Low        **Low**
      **High**      **High**   Low        **High**   **Low**
      **High**      Low        **High**   **High**   **Low**
      Low           **High**   **High**   **High**   **Low**
  6   **High**      **High**   **High**   **High**   **Low**

Bold, favorable prognosis groups in univariate survival analysis. *STAT*, signal transducer and activator of transcription.

###### 

Grouping information for joint effects analysis of four selected *STAT* genes.

                          Composition                                    
  ----------------------- ------------- ---------- ---------- ---------- ---------
  ([@b1-ol-0-0-11287])    Low           Low        Low        Low        --
  ([@b2-ol-0-0-11287])    **High**      Low        Low        Low        --
                          Low           **High**   Low        Low        --
                          Low           Low        **High**   Low        --
                          Low           Low        Low        **High**   --
                          **High**      **High**   Low        Low        --
                          **High**      Low        **High**   Low        --
                          **High**      Low        Low        **High**   --
                          Low           **High**   **High**   Low        --
                          Low           **High**   Low        **High**   --
                          Low           Low        **High**   **High**   --
                          **High**      **High**   **High**   Low        --
                          **High**      **High**   Low        **High**   --
                          **High**      Low        **High**   **High**   --
                          Low           **High**   **High**   **High**   --
  ([@b3-ol-0-0-11287])    **High**      **High**   **High**   **High**   --
  ([@b4-ol-0-0-11287])    Low           Low        Low        --         High
  ([@b5-ol-0-0-11287])    **High**      Low        Low        --         High
                          Low           **High**   Low        --         High
                          Low           Low        **High**   --         High
                          Low           Low        Low        --         **Low**
                          **High**      **High**   Low        --         High
                          **High**      Low        **High**   --         High
                          **High**      Low        Low        --         **Low**
                          Low           **High**   **High**   --         High
                          Low           **High**   Low        --         **Low**
                          Low           Low        **High**   --         **Low**
                          **High**      **High**   **High**   --         High
                          **High**      **High**   Low        --         **Low**
                          **High**      Low        **High**   --         **Low**
                          Low           **High**   **High**   --         **Low**
  ([@b6-ol-0-0-11287])    **High**      **High**   **High**   --         **Low**
  ([@b7-ol-0-0-11287])    Low           Low        --         Low        High
  ([@b8-ol-0-0-11287])    **High**      Low        --         Low        High
                          Low           **High**   --         Low        High
                          Low           Low        --         **High**   High
                          Low           Low        --         Low        **Low**
                          **High**      **High**   --         Low        High
                          **High**      Low        --         **High**   High
                          **High**      Low        --         Low        **Low**
                          Low           **High**   --         **High**   High
                          Low           **High**   --         Low        **Low**
                          Low           Low        --         **High**   **Low**
                          **High**      **High**   --         **High**   High
                          **High**      **High**   --         Low        **Low**
                          **High**      Low        --         **High**   **Low**
                          Low           **High**   --         **High**   **Low**
  ([@b9-ol-0-0-11287])    **High**      **High**   --         **High**   **Low**
  ([@b10-ol-0-0-11287])   Low           --         Low        Low        High
  ([@b11-ol-0-0-11287])   **High**      --         Low        Low        High
                          Low           --         **High**   Low        High
                          Low           --         Low        **High**   High
                          Low           --         Low        Low        **Low**
                          **High**      --         **High**   Low        High
                          **High**      --         Low        **High**   High
                          **High**      --         Low        Low        **Low**
                          Low           --         **High**   **High**   High
                          Low           --         **High**   Low        **Low**
                          Low           --         Low        **High**   **Low**
                          **High**      --         **High**   **High**   High
                          **High**      --         **High**   Low        **Low**
                          **High**      --         Low        **High**   **Low**
                          Low           --         **High**   **High**   **Low**
  ([@b12-ol-0-0-11287])   **High**      --         **High**   **High**   **Low**
  ([@b13-ol-0-0-11287])   --            Low        Low        Low        High
  ([@b14-ol-0-0-11287])   --            **High**   Low        Low        High
                          --            Low        **High**   Low        High
                          --            Low        Low        **High**   High
                          --            Low        Low        Low        **Low**
                          --            **High**   **High**   Low        High
                          --            **High**   Low        **High**   High
                          --            **High**   Low        Low        **Low**
                          --            Low        **High**   **High**   High
                          --            Low        **High**   Low        **Low**
                          --            Low        Low        **High**   **Low**
                          --            **High**   **High**   **High**   High
                          --            **High**   **High**   Low        **Low**
                          --            **High**   Low        **High**   **Low**
                          --            Low        **High**   **High**   **Low**
  ([@b15-ol-0-0-11287])   --            **High**   **High**   **High**   **Low**

'−', gene not selected. Bold, favorable prognosis groups in univariate survival analysis. *STAT*, signal transducer and activator of transcription.

###### 

Grouping information for joint effects analysis of three selected *STAT* genes.

           Composition                                    
  -------- ------------- ---------- ---------- ---------- ---------
  i        Low           Low        Low        --         --
  ii       **High**      Low        Low        --         --
           Low           High       Low        --         --
           Low           Low        **High**   --         --
           **High**      **High**   Low        --         --
           **High**      Low        **High**   --         --
           Low           **High**   **High**   --         --
  iii      **High**      **High**   **High**   --         --
  iv       Low           Low        --         Low        --
  v        Low           Low        --         Low        --
           **High**      High       --         Low        --
           **High**      **High**   --         **High**   --
           Low           **High**   --         Low        --
           Low           Low        --         **High**   --
           **High**      **High**   --         **High**   --
  vi       **High**      **High**   --         **High**   --
  vii      Low           Low        --         --         High
  viii     **High**      Low        --         --         High
           Low           **High**   --         --         High
           Low           Low        --         --         **Low**
           **High**      **High**   --         --         High
           **High**      Low        --         --         **Low**
           Low           **High**   --         --         **Low**
  ix       **High**      **High**   --         --         **Low**
  x        Low           --         Low        Low        --
  xi       **High**      --         Low        Low        --
           Low           --         **High**   Low        --
           Low           --         Low        **High**   --
           **High**      --         **High**   Low        --
           **High**      --         Low        **High**   --
           Low           --         **High**   **High**   --
  xii      **High**      --         **High**   **High**   --
  xiii     Low           --         Low        --         High
  xiv      **High**      --         Low        --         High
           Low           --         **High**   --         High
           Low           --         Low        --         **Low**
           **High**      --         **High**   --         High
           **High**      --         Low        --         **Low**
           Low           --         **High**   --         **Low**
  xv       **High**      --         **High**   --         **Low**
  xvi      Low           --         --         Low        High
  xvii     **High**      --         --         Low        High
           Low           --         --         **High**   High
           Low           --         --         Low        Low
           High          --         --         **High**   High
           **High**      --         --         Low        **Low**
           Low           --         --         **High**   **Low**
  xviii    **High**      --         --         **High**   **Low**
  xiv      --            Low        Low        Low        --
  xx       --            **High**   Low        Low        --
           --            Low        **High**   **High**   --
           --            Low        Low        Low        --
           --            **High**   **High**   **High**   --
           --            **High**   Low        Low        --
           --            Low        **High**   **High**   --
  xxi      --            **High**   **High**   **High**   --
  xxii     --            Low        Low        --         High
  xxiii    --            **High**   Low        --         High
           --            Low        **High**   --         High
           --            Low        Low        --         **Low**
           --            **High**   **High**   --         High
           --            **High**   Low        --         **Low**
           --            Low        **High**   --         **Low**
  xxiv     --            **High**   **High**   --         **Low**
  xxv      --            Low        --         Low        High
  xxvi     --            **High**   --         **High**   High
           --            Low        --         Low        High
           --            Low        --         Low        Low
           --            **High**   --         **High**   High
           --            **High**   --         **High**   **Low**
           --            Low        --         Low        **Low**
  xxvii    --            **High**   --         **High**   **Low**
  xxviii   --            --         Low        Low        High
  xxix     --            --         **High**   **High**   High
           --            --         Low        Low        High
           --            --         Low        Low        **Low**
           --            --         **High**   **High**   High
           --            --         **High**   **High**   **Low**
           --            --         Low        Low        **Low**
  xxx      --            --         **High**   **High**   **Low**

'−', gene not selected. Bold, favorable prognosis groups in univariate survival analysis. STAT, signal transducer and activator of transcription.

###### 

Grouping information for joint effects analysis of two selected *STAT* genes

           Composition                                    
  -------- ------------- ---------- ---------- ---------- ---------
  I        Low           Low        --         --         --
  II       **High**      Low        --         --         --
           Low           **High**   --         --         --
  III      **High**      **High**   --         --         --
  IV       Low           --         Low        --         --
  V        **High**      --         Low        --         --
           Low           --         **High**   --         --
  VI       **High**      --         **High**   --         --
  VII      Low           --         --         Low        --
  VIII     Low           --         --         **High**   --
           **High**      --         --         Low        --
  IX       **High**      --         --         **High**   --
  X        Low           --         --         --         High
  XI       Low           --         --         --         **Low**
           **High**      --         --         --         High
  XII      **High**      --         --         --         **Low**
  XIII     --            Low        Low        --         --
  XIV      --            **High**   Low        --         --
           --            Low        **High**   --         --
  XV       --            **High**   **High**   --         --
  XVI      --            Low        --         Low        --
  XVII     --            Low        --         High       --
           --            **High**   --         Low        --
  XVIII    --            **High**   --         **High**   --
  XIX      --            Low        --         --         High
  XX       --            Low        --         --         **Low**
           --            **High**   --         --         High
  XXI      --            **High**   --         --         **Low**
  XXII     --            --         Low        Low        --
  XXIII    --            --         Low        **High**   --
           --            --         **High**   Low        --
  XXIV     --            --         **High**   **High**   --
  XXV      --            --         Low        --         High
  XXVI     --            --         Low        --         **Low**
           --            --         **High**   --         High
  XXVII    --            --         **High**   --         **Low**
  XXVIII   --            --         --         Low        High
  XXIV     --            --         --         Low        **Low**
           --            --         --         **High**   High
  XXX      --            --         --         **High**   **Low**

'−', gene not selected. Bold, favorable prognosis groups in univariate survival analysis. STAT, signal transducer and activator of transcription.

###### 

Joint effects analysis of the prognostic value of combinations of gene expression in skin cutaneous melanoma.

  Group                   No. of genes   Patients (n=458)   No. of events (%)   MST (days)   Log-rank P-value                                        HR (95% CI)
  ----------------------- -------------- ------------------ ------------------- ------------ ------------------------------------------------------- ----------------------
  1                       5              38                 24 (63.1)           1,301        Ref.                                                    Ref.
  2                       5              87                 46 (52.9)           2,030        0.073                                                   0.636 (0.487--1.043)
  3                       5              106                53 (50.0)           1,766        0.094                                                   0.661 (0.407--1.073)
  4                       5              98                 37 (37.8)           3,196        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.352 (0.210--0.590)
  5                       5              93                 42 (45.2)           4,533        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.322 (0.194--0.535)
  6                       5              36                 17 (47.2)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.280 (0.149--0.528)
  ([@b1-ol-0-0-11287])    4              71                 42 (59.2)           1,441        Ref.                                                    Ref.
  ([@b2-ol-0-0-11287])    4              301                140 (46.4)          2,192        0.014^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.648 (0.458--0.915)
  ([@b3-ol-0-0-11287])    4              86                 37 (43.0)           4,930        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.376 (0.241--0588)
  ([@b4-ol-0-0-11287])    4              61                 37 (60.7)           1,197        Ref.                                                    Ref.
  ([@b5-ol-0-0-11287])    4              351                160 (45.6)          2,829        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.515 (0.360--0.738)
  ([@b6-ol-0-0-11287])    4              46                 22 (47.8)           5,237        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.312 (0.182--0.535)
  ([@b7-ol-0-0-11287])    4              47                 27 (57.4)           1,354        Ref.                                                    Ref.
  ([@b8-ol-0-0-11287])    4              365                171 (46.8)          2,470        0.002^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.530 (0.352--0.798)
  ([@b9-ol-0-0-11287])    4              46                 21 (45.7)           3,266        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.370 (0.189--0.601)
  ([@b10-ol-0-0-11287])   4              56                 34 (60.7)           1,354        Ref.                                                    Ref.
  ([@b11-ol-0-0-11287])   4              351                160 (45.6)          2,588        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.484 (0.333--0.704)
  ([@b12-ol-0-0-11287])   4              51                 25 (49.0)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.338 (0.200--0.573)
  ([@b13-ol-0-0-11287])   4              42                 26 (61.9)           1,354        Ref.                                                    Ref.
  ([@b14-ol-0-0-11287])   4              372                171 (46.0)          2,588        0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.498 (0.328--0.755)
  ([@b15-ol-0-0-11287])   4              44                 22 (50.0)           2,927        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.344 (0.193--0.612)
  i                       3              130                75 (57.7)           1,441        Ref.                                                    Ref.
  ii                      3              250                112 (44.8)          2,273        0.022^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.710 (0.529--0.952)
  iii                     3              103                46 (44.7)           4,930        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.418 (0.289--0.605)
  iv                      3              91                 47 (51.6)           1,949        Ref.                                                    Ref.
  v                       3              267                131 (49.1)          2,071        0.086                                                   0.746 (0.534--1.042)
  vi                      3              125                51 (40.8)           4,930        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.415 (0.278--0.620)
  vii                     3              78                 44 (56.4)           1,197        Ref.                                                    Ref.
  viii                    3              312                146 (46.8)          2,470        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.530 (0.377--0.744)
  ix                      3              93                 39 (41.9)           4,526        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.328 (0.212--0.508)
  x                       3              103                61 (59.2)           1,487        Ref.                                                    Ref.
  xi                      3              245                127 (51.8)          1,864        0.127                                                   0.788 (0.580--1.070)
  xii                     3              135                60 (44.4)           4,533        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.388 (0.270--0.557)
  xiii                    3              95                 55 (57.9)           1,354        Ref.                                                    Ref.
  xiv                     3              276                152 (551)           2,889        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.480 (0.348--0.661)
  xv                      3              112                50 (44.6)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.367 (0.249--0.542)
  xvi                     3              69                 40 (58.0)           1,429        Ref.                                                    Ref.
  xvii                    3              324                148 (45.7)          2,588        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.502 (0.352--0.715)
  xviii                   3              90                 40 (44.4)           3,266        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.358 (0.229--0.559)
  xix                     3              87                 51 (58.6)           1,655        Ref.                                                    Ref.
  xx                      3              268                121 (45.1)          2,367        0.012^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.658 (0.474--0.913)
  xxi                     3              128                57 (44.5)           4,507        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.419 (0.286--0.613)
  xxii                    3              70                 43 (61.4)           1,301        Ref.                                                    Ref.
  xxiii                   3              328                148 (45.1)          2,948        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.530 (0.377--0.745)
  xxiv                    3              85                 38 (44.7)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.348 (0.223--0.542)
  xxv                     3              66                 35 (53.0)           1,910        Ref.                                                    Ref.
  xxvi                    3              323                150 (46.4)          2,470        0.043^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.683 (0.472--0.988)
  xxvii                   3              94                 44 (46.8)           3,266        0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.462 (0.294--0.724)
  xxviii                  3              70                 40 (57.1)           1,486        Ref.                                                    Ref.
  xxix                    3              323                149 (46.1)          2,470        0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.536 (0.376--0.764)
  xxx                     3              90                 40 (44.4)           5,237        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.349 (0.223--0.545)
  I                       2              139                70 (50.4)           1,949        Ref.                                                    Ref.
  II                      2              180                92 (51.1)           2,005        0.519                                                   0.902 (0.660--1.233)
  III                     2              164                67 (40.9)           4,526        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.485 (0.346--0.678)
  IV                      2              168                96 (57.1)           1,487        Ref.                                                    Ref.
  V                       2              122                48 (39.3)           2,454        0.017^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.655 (0.462--0.928)
  VI                      2              193                85 (44.0)           3,564        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.477 (0.356--0.641)
  VII                     2              133                70 (52.6)           1,780        Ref.                                                    Ref.
  VIII                    2              192                90 (46.9)           2,273        0.008^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.654 (0.477--0.897)
  IX                      2              133                59 (44.4)           4,507        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.449 (0.316--0.638)
  X                       2              125                70 (56.0)           1,438        Ref.                                                    Ref.
  XI                      2              208                94 (45.2)           3,080        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.483 (0.353--0.662)
  XII                     2              125                55 (44.0)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.435 (0.304--0.623)
  XIII                    2              130                75 (57.7)           1,441        Ref.                                                    Ref.
  XIV                     2              198                84 (42.4)           2,545        0.011^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.677 (0.488--0.912)
  XV                      2              130                60 (46.2)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.466 (0.332--0.656)
  XVI                     2              148                72 (48.6)           1,992        Ref.                                                    Ref.
  XVII                    2              162                80 (49.4)           2,071        0.297                                                   0.843 (0.612--1.162)
  XVIII                   2              148                67 (45.3)           3,259        0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.564 (0.403--0.791)
  XIX                     2              111                61 (54.9)           1,910        Ref.                                                    Ref.
  XX                      2              236                106 (44.9)          3,080        0.008^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.652 (0.476--0.894)
  XXI                     2              111                52 (46.8)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.508 (0.349--0.739)
  XXII                    2              141                77 (54.6)           1,780        Ref.                                                    Ref.
  XXIII                   2              176                78 (44.3)           2,192        0.015^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.674 (0.490--0.926)
  XXIV                    2              141                64 (45.4)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.466 (0.333--0.653)
  XXV                     2              118                65 (55.1)           1,544        Ref.                                                    Ref.
  XXVI                    2              222                106 (47.4)          3,136        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.548 (0.400--0.750)
  XXVII                   2              118                48 (40.7)           3,259        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.399 (0.273--0.583)
  XXVIII                  2              105                56 (53.3)           1,780        Ref.                                                    Ref.
  XXIX                    2              248                114 (46.0)          2,470        0.013^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^     0.667 (0.484--0.920)
  XXX                     2              105                49 (46.7)           3,424        \<0.001^[a](#tfn9-ol-0-0-11287){ref-type="table-fn"}^   0.466 (0.314--0.692)

P\<0.05. MST, median survival time; HR, hazard ratio; CI, confidence interval; Ref., reference.

[^1]: Contributed equally
